Weight ManagementAlso known as: CKGGRAKDC-GG-D(KLAKLAK)2, Prohibitin-targeting peptide, fat-destroying peptide
Adipotide
Peptidomimetic that selectively targets and destroys blood vessels supplying white adipose tissue — demonstrated rapid fat loss in primate studies but carries significant risk of renal toxicity.
Half-Life
~2-4 hours (estimated)
Dose Range
0.5-1 mg/kg (research)
Frequency
Per study protocol
Vial Sizes
5 mg
Mechanism of Action
Contains a prohibitin-targeting domain (CKGGRAKDC) that binds prohibitin on adipose vasculature endothelium, fused to a pro-apoptotic peptide D(KLAKLAK)2 that disrupts mitochondrial membranes. Causes selective apoptosis of adipose blood vessels, leading to fat tissue ischemia and resorption.
Source: PMID: 22100857
Dosing Protocol
| Typical Dose | 0.5-1 mg/kg (research) |
| Frequency | Per study protocol |
| Half-Life | ~2-4 hours (estimated) |
| Common Vial Sizes | 5 mg |
Reconstitution Example
Vial
5 mg
Water
2 mL
Concentration
2.5 mg/mL
Per Unit (100u syringe)
25 mcg
Dose of 500 mcg = 20 units on a 100-unit insulin syringe
Dosing Quick Reference
Adipotide— Dosing Guide
Dose Range
0.5-1 mg/kg (research)
Half-Life
~2-4 hours (estimated)
Frequency
Per study protocol
Route
Subcutaneous
5 mg vial
💧 2 mL BAC water|📐 2.5 mg/mL concentration|💉 25 mcg/unit (100u syringe)
Weight Managementcalcmypeptide.com
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code